Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Will Vectura update on key drug?
Wednesday 6 September
It has been a difficult year for pharmaceuticals firm Vectura (VEC). Since May, the company’s share price has plummeted by 25% after the US Food and Drug Administration temporarily blocked the launch of Hikma’s (HIK) generic asthma treatment VR315.
This had a negative read-across for Vectura as VR315 is based on its dry powder inhaler tech so investors will be keen for updates on a potential launch when the firm reports its interim results on 6 September.